At the Annual World Muscle Society Congress, we're presenting six posters across our neuromuscular portfolio highlighting our work in Duchenne, Friedreich's ataxia and our proprietary POLARIS-101™ capsid, which is designed to enable safe and effective gene therapy delivery and has shown encouraging clinical signals in #Duchenne. We look forward to connecting with leading global experts to advance scientific progress in rare neuromuscular diseases. #WMS2026 #SolidInside

We look forward to attending the Annual Neuromuscular Study Group Scientific Meeting, where we'll share two posters highlighting our work in #Duchenne, including our POLARIS-101™ capsid and our Phase 1/2 INSPIRE DUCHENNE study. We value opportunities to engage with researchers, clinicians and advocates working to shape the future of patient care. #SolidInside #RareDisease

In honor of #WorldDuchenneAwarenessDay, we joined @JettFoundation at the Gals for Cal women's triathlon, coming together with the community to raise awareness, recognize progress and advance a future that is #StrongerThanDuchenne. Every day, we're proud to support greater access to care, continued research and inclusive experiences for individuals living with Duchenne. #WDAD2026

$SLDB: Today, our CEO Bo Cumbo will participate in a fireside chat at the @HCWCO 28th Annual Global Investment Conference. Join us live or watch the replay here: investors.solidbio.com/news-…

$SLDB: This week, our CEO Bo Cumbo and CMO Gabriel Brooks will participate in fireside chats at the @Official_Cantor Global Healthcare Conference and the @Citi Biopharma Back to School Summit. Tune in live or watch the replay here: investors.solidbio.com/news-…

Today on #WorldDuchenneAwarenessDay, we reflect on the profound impact that access to care, resources, scientific breakthroughs and opportunities can have for individuals and families affected by #Duchenne. We remain committed to advancing research and innovation, working alongside the Duchenne community in pursuit of meaningful progress. #WDAD2026 #RareDisease

Improving access for individuals living with Duchenne is about more than healthcare. It's about creating opportunities to fully participate in their communities and engage in activities they love. As we approach #WorldDuchenneAwarenessDay, we reflect on the importance of expanding access, and we stand with the Duchenne community in raising awareness, driving innovation and removing barriers. Read more from Annie Ganot, Solid Co-Founder, SVP Patient Advocacy and Duchenne mom. #WDAD2026 #RareDisease

$SLDB: We're looking forward to attending several investor conferences this month, where members of management will join fireside chats to discuss Solid's strategy and recent progress. Read more: investors.solidbio.com/news-…

Ahead of #WorldDuchenneAwarenessDay on September 7, we're joining the global Duchenne community in recognizing this year's theme, "Access Changes Lives." Access is a fundamental driver of better outcomes for individuals living with #Duchenne. This year's theme focuses on removing barriers to knowledge, research and support, helping people make informed decisions and creating opportunities to live full lives. Learn more from @worldduchenne: worldduchenne.org/world-duch… #WDAD2026 #RareDisease

Recently, we joined @PPDCRO at their GMP Lab in Middleton, WI, for a discussion with patient advocates in the #FriedreichsAtaxia (FA) community. This panel featured firsthand perspectives from those impacted by FA and insights into our work in FA, fostering a deeper understanding of the patient and caregiver experience. We're proud to be part of important conversations that strengthen collaboration and advance our shared goal of improving outcomes for people in need. Thank you to Sam, Aiden and Rachel for sharing your stories! #FACommunity #RareDisease

Solid Biosciences today announced our financial results for the second quarter of 2026, along with business and pipeline updates. Read the full release: investors.solidbio.com/news-… #SolidBiosciences $SLDB

This weekend, #TeamSolid had a great time at the fourth annual rideATAXIA Hometown Boston bike ride, hosted by Friedreich's Ataxia Research Alliance (FARA). We're proud to join FARA and the local Boston community in advancing Friedreich's ataxia (FA) research. #FriedreichsAtaxia #FACommunity

We’re proud to sponsor The Akari Foundation’s Duchenne Family Education & Community Connection Event on August 1, bringing together individuals and families in the Duchenne community to learn, connect and access valuable resources. The Akari Foundation is dedicated to educating and empowering the Hispanic community affected by rare neuromuscular diseases, providing them with equitable access to information, awareness and advocacy for comprehensive support. We look forward to connecting with the Duchenne community throughout the event. Learn more about The Akari Foundation: theakarifoundation.org/nosot… #RareDisease #PatientAdvocacy #Duchenne #MuscularDystrophy

With summer officially underway, we want to recognize the incredible impact our spring co-op cohort made over the past several months. Their hard work directly supported our mission to improve the lives of patients living with rare diseases. Day in and day out, they brought dedication, curiosity and passion to our teams. We are proud of their accomplishments during their time with us and wish them nothing but the best as they take the next steps in their careers! #TogetherWeAreSolid #SolidInside #SolidStartsHere

Solid Biosciences is looking forward to attending the 2026 Leerink Partners Therapeutics Forum in Boston on July 15, where members of the management will participate in 1x1 investor meetings. If you will be attending, we’d welcome the chance to connect. #SLDB #SolidBiosciences #Biotech #RareDisease #LeerinkPartners